Stay updated with breaking news from Expanded Indication. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Amgen Inc.’s treatment Otezla was approved by the U.S. Food and Drug Administration to treat adults with all levels of plaque psoriasis.
(2) NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat. Read on. 1.KemPharm Scores FDA Nod For ADHD Drug KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of...
Share this article Share this article ResearchAndMarkets.com's offering. In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026. The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predo...